Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations - PubMed
4 hours ago
- #ocular complications
- #GLP-1 receptor agonists
- #diabetic retinopathy
- GLP-1 RAs are central to T2DM management but have concerning ocular safety profiles.
- Clinical trials like SUSTAIN-6 show higher DR incidence with semaglutide, especially in pre-existing DR cases.
- REWIND and LEADER trials found no significant DR, indicating variability among agents.
- Observational studies present mixed findings on DR progression risk with GLP-1 RAs.
- Recent reports link GLP-1 RAs, particularly semaglutide, to NAION, prompting regulatory scrutiny.
- Some real-world data suggest GLP-1 RAs may protect against other retinal disorders like neovascular AMD and DME.
- Mechanisms involve rapid metabolic shifts, vascular dysregulation, and potential direct effects on ocular tissues.
- Ocular risks are concentrated in high-risk subgroups, necessitating individualized prescribing and monitoring.
- Baseline ophthalmic assessment and interdisciplinary monitoring are recommended until long-term impacts are clear.